Perspectives on Tuberculosis Pathogenesis and Discovery of Anti-Tubercular Drugs

被引:7
作者
Ntie-Kang, Fidele [1 ,2 ,3 ]
Yong, Joseph N. [4 ]
Owono, Luc C. Owono [1 ,5 ]
Sippl, Wolfgang [3 ]
Megnassan, Eugene [6 ]
机构
[1] Univ Douala, Fac Sci, CEPAMOQ, Douala, Cameroon
[2] Univ Buea, Fac Sci, Dept Chem, Chem & Bioact Informat Ctr, Buea, Cameroon
[3] Univ Halle Wittenberg, Dept Pharmaceut Sci, D-06120 Halle, Saale, Germany
[4] Univ Buea, Fac Sci, Dept Chem, Buea, Cameroon
[5] Univ Yaounde I, Ecole Normale Super, Lab Simulat & Biomol Phys, Yaounde, Cameroon
[6] Univ Abobo Adjame, Lab Fundamental & Appl Phys, Abidjan, Cote Ivoire
关键词
Drug discovery; drug resistance; in silico screening; tuberculosis; HIGH-THROUGHPUT DOCKING; MYCOBACTERIUM-TUBERCULOSIS; NATURAL-PRODUCTS; IN-VITRO; ANTIMYCOBACTERIAL ACTIVITY; COMBINATORIAL CHEMISTRY; ASPARTIC PROTEASE; POTENT INHIBITORS; THYMIDINE ANALOGS; MEDICINAL-PLANTS;
D O I
10.2174/0929867321666140706144933
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Based on the global burden of tuberculosis and resistant strains that have recently emerged, not responding to existing therapies, it has become urgent to search for new remedies against this global human plague that has been compounded by HIV co-infection. Thus, the search for new drugs against the disease-causing agent, Mycobacterium tuberculosis (MTB), is an ongoing effort. This review discusses the state-of-the-art in anti-tuberculosis pathogenesis and anti-TB drug research, identifying some of the challenges being faced by researchers in the field and sheds light on possible ways forward, particularly in low-income countries.
引用
收藏
页码:3466 / 3477
页数:12
相关论文
共 153 条
[61]   Recent development and application of virtual screening in drug discovery: An overview [J].
Hou, TJ ;
Xu, XJ .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (09) :1011-1033
[62]   Rational drug discovery: what can we learn from regulatory networks? [J].
Huang, S .
DRUG DISCOVERY TODAY, 2002, 7 (20) :S163-S169
[63]   Novel paradigms for drug discovery: computational multitarget screening [J].
Jenwitheesuk, Ekachai ;
Horst, Jeremy A. ;
Rivas, Kasey L. ;
Van Voorhis, Wesley C. ;
Samudrala, Ram .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (02) :62-71
[64]   Computational approaches to structure-based ligand design [J].
Joseph-McCarthy, D .
PHARMACOLOGY & THERAPEUTICS, 1999, 84 (02) :179-191
[65]  
Kaelin William G Jr, 2004, Sci STKE, V2004, ppe12, DOI 10.1126/stke.2252004pe12
[66]   Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study [J].
Keung, ACF ;
Owens, RC ;
Eller, MG ;
Weir, SJ ;
Nicolau, DP ;
Nightingale, CH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1230-1233
[67]  
Kubinyi H, 1998, Curr Opin Drug Discov Devel, V1, P16
[68]   CoMFA based de novo design of pyrrolidine carboxamides as inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis [J].
Kumar, Ashutosh ;
Siddiqi, Mohammad Imran .
JOURNAL OF MOLECULAR MODELING, 2008, 14 (10) :923-935
[69]   In vitro inhibition of drug-resistant and drug-sensitive strains of Mycobacterium tuberculosis by ethnobotanically selected South African plants [J].
Lall, N ;
Meyer, JJM .
JOURNAL OF ETHNOPHARMACOLOGY, 1999, 66 (03) :347-354
[70]   Antimycobacterial activity of diospyrin derivatives and a structural analogue of diospyrin against Mycobacterium tuberculosis in vitro [J].
Lall, N ;
Das Sarma, M ;
Hazra, B ;
Meyer, JJM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (02) :435-438